IL-13Rα1 Expression on β-Cell–Specific T Cells in NOD Mice by Rasche, Sarah S. et al.
IL-13Ra1 Expression on b-Cell–Speciﬁc T Cells in
NOD Mice
Sarah S. Rasche,
1 Michele Phillips,
1 Marcia F. McInerney,
2,3 Eli E. Sercarz,
4 and Anthony Quinn
1
OBJECTIVE—Immunotherapy using peptides from the b-cell
antigen GAD65 can preserve glucose homeostasis in diabetes-
prone NOD mice; however, the precise mechanisms that arrest
islet-reactive T cells remain unresolved. Our previous work
revealed that a dominant GAD65 epitope contained two overlap-
ping I-A
g7–restricted determinants, 524-538 and 530-543, with the
former associated with amelioration of hyperglycemia. Here, we
sought to discover whether p524-538–speciﬁc T cells could di-
rectly regulate islet-reactive T cells.
RESEARCH DESIGN AND METHODS—Prediabetic NOD mice
were used to determine the relationship between peptide p524-
538–induced interleukin (IL)-13 and regulation of islet autoimmu-
nity. Pancreatic lymph node (PLN) cells from mice at distinct
stages of islet inﬂammation, peri-insulitis versus invasive insulitis,
were harvested to establish the expression pattern of IL-13 re-
ceptor a1 (IL-13Ra1) on islet-associated T cells.
RESULTS—Peptide p524-538 preferentially induced IL-13–
producing T cells that antagonized the release of g-interferon
by spontaneously arising GAD65 autoimmunity, and recombinant
human IL-13 inhibited proliferation of islet-reactive clonotypic
T cells. A subset of CD4
+ T cells in NOD and NOD.BDC2.5 T cell
receptor transgenic mice expressed functional IL-13Ra1, which
induced phosphorylation of signal transducer and activator of
transcription 6 in the presence of cognate cytokine. Notably,
the number of IL-13Ra1
+ T cells was heightened in the PLN of
young NOD mice when compared with older female counterparts
with advanced insulitis. Immunization with p524-538 preserved
IL-13Ra1 expression on PLN T cells.
CONCLUSIONS—IL-13 may be important for regulating auto-
immunity in the early stages of insulitis, and the loss of IL-13Ra1
on islet-reactive T cells may be a biomarker for fading regional
immune regulation and progression to overt diabetes. Diabetes
60:1716–1725, 2011
T
he NOD mouse is a prototypical model of in-
ﬂammatory autoimmune disease that displays
many of the characteristics of human type 1 di-
abetes (1). No cure has been identiﬁed for the
disease, but several interventions are able to arrest islet in-
ﬂammation and prevent or delay the onset of hyperglycemia
in NOD mice. Such ﬁndings and ongoing human clinical
trials suggest that the targeting of autoantigen-speciﬁc
T cells offers prospects for successful treatment of newly-
diagnosed disease (2). Glutamic acid decarboxylase (GAD65)
has persisted as a prominent therapeutic target, which
when delivered as a protein (3,4), peptide (5,6), gene
encoding plasmid (7), or major histocompatibility complex
peptide:ligand (8) provides amelioration from insulitis and
b-cell destruction. However, in spite of much success, a
deﬁned mode by which such therapies engage islet-reactive
T cells is often lacking or has not extended beyond the
notion of an altered cytokine milieu. Given the complexity
of cytokine activities, a clear understanding of the mecha-
nistic actions in GAD65-speciﬁc interventions is needed to
improve upon existing therapies.
GAD65 peptide p524-543 is an immunogen that has been
associated with both protection (9,10) and progression of
diabetes (11,12) in NOD mice. Previously we showed that
two I-A
g7–restricted determinants were contained within
the p524-543 sequence, in which 530-543 (p530)-speciﬁcT
cells appeared naturally in young naïve NOD mice (9,13),
whereas 524-538 (p524)-speciﬁc T cells were primed and
expanded following immunization with peptides p524-543
or p524 (9). Thus, the endogenous response focuses on
sequences in the carboxyl-terminal portion of 524-543
(9,14), but active immunization with 524-543 switched the
dominance to the amino portion of the molecule. Re-
markably, active induction of an immune response to p524
signiﬁcantly reduced the incidence of hyperglycemia in the
aggressive cyclophosphamide-induced model of diabetes
(9), and adoptive transfer of cloned p524-reactive T cells
blocked the progression of insulitis and hyperglycemia (9).
The appearance of a robust p524-speciﬁc response was
also linked to a loss of the spontaneous p530-speciﬁc pro-
liferative response (9), suggesting that the p524 immune
response could antagonize islet-reactive T cells that gather
in the early stages of insulitis.
In this study, we investigated the nature of the p524-
induced regulation of spontaneous autoimmunity and
found that the peptide preferentially induces interleukin
(IL)-13 that is able to modulate b-cell–speciﬁca u t o i m m u -
nity and directly alters the activities of islet-reactive T cells.
Furthermore, expression of the cognate receptor, IL-13 re-
ceptor a1 (IL-13Ra1), was most prevalent among T cells in
the pancreatic lymph nodes (PLNs) of young prediabetic
NOD mice. Thus, although treatment with islet antigens
may lead to the release of regulatory cytokines into the
milieu, here we provide evidence that IL-13 can directly
regulate T cells in the islets of young NOD mice.
RESEARCH DESIGN AND METHODS
Mice and cell lines. NOD mice were purchased from Taconic Farms
(Germantown, NY) or bred in the University of Toledo Animal Care Facility.
NOD.BDC2.5 T-cell receptor (TCR) transgenic (Tg) mice were purchased from
Jackson Laboratories (Bar Harbor, ME). The EL4 cell line (ATCC, Manassas,
VA) was cultured in complete medium (RPMI-1640 supplemented with 10%
horse serum).
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ORIGINAL ARTICLEPeptides and T-cell lines. GAD65 peptides 524-543, 524-538 (p524), and 530-
543 (p530),and hen eggwhite lysozyme peptide HEL 11–25 weresynthesized as
described previously (9). The p524-reactive T-cell clone GAD35Za was isolated
from peptide-immunized mice (9). Brieﬂy, spleen and lymph node cells from
NOD mice immunized with p524-538 (20 mg of peptide p524 in complete
Freund’s adjuvant) were challenged in vitro with cognate peptide, and ex-
panded with recombinant human IL-2 (rIL-2). T-cell clones were isolated by
limiting dilution, and maintained by cycles of restimulation with p524-pulsed
irradiated syngeneic spleen cells and expansion with rIL-2.
Cytokine enzyme-linked immunospot and enzyme-linked immunosor-
bent assay. To enumerate endogenously primed p530-speciﬁc T cells via
enzyme-linked immunospot (ELISPOT), spleen cells from naïve female NOD
mice were cultured in 24-well plates with GAD65 peptide 524-543 as previously
described (15). Alternatively, to detect responses by enzyme-linked immuno-
sorbent assay (ELISA), spleen cells collected from the 24-well plates were
resuspended in complete medium and added to 96-well round-bottom plates,
with or without GAD65 peptide p530. Twenty-four to 72 h later, the culture
supernatants were collected and tested for the presence of cytokines (9).
To evaluate p524 responses in vivo, 2- to 3-week-old NOD mice were im-
munized, once or twice, in the peritoneum with 100 mg of p524, HEL 11–25, or
PBS, emulsiﬁed in incomplete Freund’s adjuvant (IFA). Four or 9 weeks later,
lymphoid tissues were collected and analyzed by ELISPOT or ELISA, or ﬂow
cytometry, respectively.
For transwell experiments, GAD35Za clonotypic cells (5 3 10
5 cells/mL)
were coplated with irradiated syngeneic spleen cells (4 3 10
6 cells/mL) in the
upper chamber of 24-transwell plates, and spleen cells from naïve 6- to 8-week-
old NOD mice were plated at 1 3 10
7cells/mL in the lower chamber. Mono-
clonal antibody (10 mg/mL) to g-interferon (IFN-g)( R 4 –6A2), IL-5 (TRFK5), or
IL-13 (MAB 413) was added to the upper wells; PBS or rat IgG (10 mg/mL) was
added to control wells. GAD65 peptide 524-543 was then added to all upper
chambers at a ﬁnal concentration of 10 mg/mL. Three days later, the spleen
cells in the lower chamber were recovered and IFN-g spot-forming cells
enumerated in duplicate wells by ELISPOT.
CD4
+ T-cell puriﬁcation. NOD or NOD.BDC2.5.TCR.Tg spleen cells were
labeled with anti-CD4–conjugated magnetic beads (Miltenyi Biotech, Auburn,
CA) and puriﬁed according to the manufacturer’s instructions. CD4
+ T-cell
enrichment (.95%) was veriﬁed by ﬂow cytometry.
Proliferationassay.To assess the effect of rIL-13 on CD4
+ T-cell proliferation,
puriﬁed NOD or BDC2.5.TCR.Tg CD4
+ T cells (6 3 10
4 cells/well) were cul-
tured on anti-CD33–coated 96-well plates for 72 h in the presence or absence
of rIL-13 (R&D Systems, Minneapolis, MN). PBS-coated wells served as neg-
ative controls. For the last 18 h of culture, wells were pulse-labeled with 1mCi/
well
3H-thymidine (MP Biomedicals, Solon, OH), harvested, and counted as
previously described (16).
RT-PCR. The expression of IL-4, IL-10, transforming growth factor (TGF)-b,
and b-actin was evaluated in GAD35Za T cells via RT-PCR. Kits containing
primers for IL-10, TGF-b,a n db-actin were purchased from R&D Systems.
Primers for IL-4 (forward CATCGGCATTTTGAACGAGGTCA, and reverse
CTTATCGATGAATCCAGGCATCG) were purchased from Operon (Alameda,
CA). Brieﬂy, GAD35Za T cells were stimulated with irradiated NOD spleen
cells in the presence of p524 (10 mg/mL) for 24 to 48 h. mRNA was harvested
with an RNeasy kit (Invitrogen, Carlsbad, CA) and used as a template for
complimentary DNA (cDNA) synthesis. RT-PCR was performed according to
the manufacturer’s instructions for the primer kits, using Platinum Taq poly-
merase (Invitrogen).
For analysis of IL-13Ra1 expression, CD4
+ T cells puriﬁed from NOD or
NOD.BDC2.5.TCR.Tg splenocytes were stimulated on anti-CD33–coated plates
for 0, 24, 48, or 72 h. The cells were harvested, and mRNA was extracted with
TRIzol (Invitrogen) and converted to cDNA. cDNA was used for quantitative
real-time RT-PCR using iQ SYBR Green Supermix (Bio-Rad, Hercules, CA).
Normalized results using the D Ct method of quantiﬁcation are expressed as
% GAPDH. The PCR primer sequences were as follows: GAPDH for-
ward CCAGGTTGTCTCCTGCGACT, reverse ATACCAGGAAATGAGCTTG
ACAAAGT; IL-13Ra1 forward GAATTTGAGCGTCTCTGTCGAA, reverse
GGTTATGCCAAATGCACTTGAG; IL-4R forward AGTGAGTGGAGTCCTA
GCATC, reverse GCTGAAGTAACAGAACAGGC.
Flow cytometry. For direct ex vivo analysis of IL-13Ra1 expression on T-cell
populations, spleens, inguinal lymph nodes (ILNs), and PLNs were harvested
from age-matched mice and stained with anti–TCR-phycoerythrin (PE)/Cy5
(BioLegend), anti–CD4-PE (BioLegend), and puriﬁed goat anti–IL-13Ra1( S a n t a
Cruz Biotechnology, Santa Cruz, CA) or puriﬁed goat IgG. The cells were then
washed and stained with donkey anti–goat IgG-ﬂuoroisothiocyanate (Southern
Biotech, Birmingham, AL), washed, and analyzed by ﬂow cytometry.
ForanalysisofIL-13signaling,PLNsfrom4-week-oldfemaleNODmicewere
harvested and stained with anti–TCR-ﬂuoroisothiocyanate (BioLegend), serum-
starved in RPMI for 1 h, and then exposed to rIL-13 for 30 min at 37°C. The
cells were washed, ﬁxed, permeabilized, and then stained with an antibody to
phosphorylated signal transducer and activator of transcription (STAT) 6
(Santa Cruz Biotechnology) or goat isotype control, followed by biotinylated
donkey anti–goat IgG and strepavidin-PE before analysis by ﬂow cytometry.
Histological evaluation. The pancreas was collected at the same time as
lymphoid tissue harvest for IL-13Ra1 evaluation. The pancreas was ﬁxed in
10% formalin, sectioned (5 micron sections, 20 microns apart), and stained
with hematoxylin and eosin. Islets were graded as normal or as having peri-
insulitis (inﬂammation only around the periphery of the islet) or invasive
insulitis (inﬂammation was greater than 33% of the islet and disrupted the
typical round/oval shape).
RESULTS
Injection with p524-538 or p524-responsive T cells
reduces the endogenous p530 response in NOD mice.
p524-543 and p530-speciﬁc IFN-g–producing cells were
prevalent in the spleens of naïve prediabetic NOD mice
(Fig. 1), but were undetectable in healthy BALB/c or
C57BL/6 mice (data not shown). However, treatment of
young 2-week-old NOD mice with p524-538/IFA led to
a signiﬁcant reduction in the endogenous p530-speciﬁc
IFN-g response, regardless of whether p524-543 or p530
was used in the challenge (Fig. 2A). In addition to blocking
hyperglycemia (10), treatment with p524 enhanced or
primed an IL-5 response to p524-543, which was restricted
to the p524 epitope and could not be recalled by the p530
peptide (Fig. 2B). Taken together, these observations in-
dicate that p524/IFA primed a p524-speciﬁc Th2 response
while concomitantly antagonizing p530-speciﬁc Th1 cells;
this correlated well with prior observations of lost pro-
liferative responses to p530 in p524-treated mice (9). Fur-
thermore, these ﬁndings support the hypothesis that the
active induction of p524-reactive T cells directly regulates
the activities of endogenously primed GAD65-speciﬁc
T cells.
Because it was possible that the observed suppression
of the p530 Th1 responses was mediated through a regu-
latory cytokine, we wanted to determine whether p524
preferentially induced a cytokine(s) known to regulate
diabetes in NOD mice. Although IL-13 and IL-5 were con-
sistently detected in recall responses of 4-week-old NOD
FIG. 1. Naïve NOD mice mount Th1 immune responses to GAD65 pep-
tide p530-543. Spleen cells pooled from three 6-week-old female NOD
mice were stimulated in vitro with peptide p524-543 (10 mg/mL) in
24-well plates. Five days later, the cells were resuspended in IFN-g
ELISPOT plates (1 3 10
6 cells/well) with the indicated concentration of
peptide GAD65 530-543 (p530). The number of spot-forming cells was
determined using a stereomicroscope, and the results are representa-
tive of four experiments.
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speciﬁc responses were marginal and rarely reached
signiﬁcant levels (Fig. 2C). Interestingly, GAD35Za se-
creted IFN-g, IL-5, and IL-13 upon antigenic challenge
(Table 1), but failed to produce IL-4 or IL-10 (Table 1). The
expression of IL-4, IL-10, and TGF-b was also undetectable
by RT-PCR in antigen-challenged GAD35Za T cells (data
not shown). Therefore, although susceptibility to auto-
immune disease in NOD mice has often been linked to a
poor Th2 response, as judged by modest IL-4 responses,
here we found NOD mice to be quite capable of generating
both IL-5 and IL-13 speciﬁc responses to p524.
p524-speciﬁc T cells regulate the p530 response via
IL-13. To demonstrate that p524-reactive T cells could
indeed alter the spontaneous p530-speciﬁc response via
release of IL-5 or IL-13 we performed experiments in
transwell plates where the upper and lower chambers
are separated by a semipermeable membrane. Naïve NOD
spleen cells were added to the lower chamber, and
GAD35Za T cells and irradiated syngeneic spleen cells
FIG. 2. Immunization with GAD65 peptide p524–538 antagonizes the endogenous Th1 response to p530–43. A and B: Six 2-week-old NOD mice were
immunized once (13) or twice (23) with 100 mg of p524–538 or PBS emulsiﬁed in IFA. Four weeks later, the spleen cells were collected and
analyzed (as in Fig. 1) to enumerate (A) IFN-g spot-forming cells or (B) IL-5 spot-forming cells, in response to challenge with p524-543 (black
bar), p530-543 (checkered), p524-538 (vertical stripes), or Concanavalin A (ConA) (diagonal stripes). Background responses to control peptide
HEL 11–25 have been subtracted. The results are representative of two experiments that yielded similar ﬁndings. In all experiments, the mean
response in peptide-treated mice was compared with control mice (IFA alone) using Student t test (**P < 0.005; ***P < 0.0005). The percentages
noted in the chart indicate the reduction in spot-forming cells compared with IFA-immunized control animals. C: Three 4-week-old NOD mice were
immunized once with 100 mg of p524-538/IFA. The individual spleens (p524) were collected 12 days later and challenged in vitro with p524-538
(10 mg/mL, black bar). Forty-eight hours later, IL-4, IL-5, IL-13, IL-10, and IFN-g levels in the supernatants were measured by ELISA. A Th0 cell
line stimulated with anti-CD3 (1.0 mg/mL, diagonal stripes) served as a positive control. The bars represent the mean concentration detected in
cultures from the three mice (minus medium controls). The data are representative of four experiments.
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to the upper chamber along with monoclonal antibody to
IL-5, IL-13, or IFN-g, or an IgG control monoclonal anti-
body (Fig. 3). The p524-543–speciﬁcI F N - g response among
the spleen cells recovered from the lower chamber was
reduced by 80% when cultured in the presence of GAD35Za
T cells (Fig. 3, control vs. PBS), consequently conﬁrming
that the inhibitory effect induced by the p524-reactive cells
was mediated by a soluble factor. Importantly, this in-
hibition was completely neutralized by antibodies to IL-13
but not by anti–IL-5, anti–IFN-g, or rat IgG (Fig. 3).
To determine whether IL-13 alone could mimic the
suppressive effect of GAD35Za T cells, mouse rIL-13, rIFN-
g, rIL-5, or rIL-4 was added to naïve NOD spleen cells
during in vitro challenge with the peptide p524-543. rIL-13
was able to signiﬁcantly reduce the p530-speciﬁcs e c r e t i o n
of IFN-g (Fig. 4A), whereas neither rIL-4, rIL-5, nor rIFN-g
had a similar inhibitory effect (Fig. 4A). The rIL-13–mediated
inhibition was not the result of cellular toxicity, since there
was no reduction in the number of spleen cells recovered
from wells cultured in the presence of this cytokine (data
not shown).
To establish whether IL-13 could directly suppress the
activities of islet-reactive T cells, NOD.BDC2.5 TCR clo-
notypic spleen cells were cultured in wells coated with
anti-CD3 in the presence or absence of rIL-13. Even in the
presence of robust antigen receptor engagement, BDC2.5,
clonotypic proliferation was inhibited by up to 87% when
stimulated in the presence of rIL-13 (Fig. 4B). Although
this approach should eliminate inﬂuences by antigen-
presenting cells, to further conﬁrm that rIL-13 was having
a direct impact on T cells and that the inhibitory response
was not peculiar to the BDC2.5 clonotypic cells, CD4
+ T
cells were puriﬁed from the spleens of naïve NOD mice
and stimulated with anti-CD3 in the presence of rIL-13.
Again, rIL-13 caused signiﬁcant suppression of the T cell
proliferative response (Fig. 4C). Similar results were ob-
served when the experiment was performed with puriﬁed
NOD.BDC2.5.TCR.Tg CD4
+ T cells (data not shown).
Subsets of NOD and NOD.BDC2.5 T cells express
a functional IL-13Ra1. Because IL-13 seemed to directly
regulate the T cells, it was necessary to demonstrate that
NOD and BDC2.5 clonotypic T cells expressed IL-13Ra1
and IL-4Ra, which heterodimerize to form the functional
complex for IL-13–mediated signaling (17,18). cDNA pro-
duced from puriﬁed NOD or NOD.BDC2.5.TCR.Tg CD4
+
splenocytes (naïve or activated) was analyzed by quanti-
tative real-time PCR using primers speciﬁc for mouse
IL-13Ra1, IL-4Ra, or IL-13Ra2. IL-13Ra1 and IL-4Ra tran-
scripts were detected in both naïve and activated T cells
(Fig. 5A). IL-13Ra1 mRNA expression was reduced fol-
lowing TCR engagement in both sets of T cells (Fig. 5A),
but IL-13Ra1 and IL-4Ra were not detectable in the EL-4
thymoma control cell line (Fig. 5A). Next, we were able to
validate the expression of IL-13Ra1 chain on NOD T cells,
as approximately 5% of the TCR
+CD4
+ cells in the spleens
TABLE 1
The T-cell clone GAD35Za produces IL-13, IL-5, and IFN-g
IL-13
ng/mL
IL-5
ng/mL
IFN-g
mg/mL
IL-4
ng/mL
IL-10
ng/mL
GAD35Za* 13.5 1.75 308 0 0
OVA-1* 0 0 130 0.5 0
*I-A
g7–restricted T clones GAD35Za and OVA-1 were plated (5 310
4/well)
with irradiated syngeneic spleen cells (5 3 10
5/well) in the presence
or absence of cognate antigen, 10 mg/mL of p524-538 or 50 mg/mL of
ovalbumin, respectively. Forty-eight hours later, the supernatants
were collected and cytokine levels determined by ELISA, as de-
scribed in RESEARCH DESIGN AND METHODS, with background levels sub-
tracted (T cells + antigen-presenting cells).
FIG. 3. IL-13 produced by p524-538–reactive T cells can antagonize the endogenous Th1 response to p530-543. GAD35Za clonotypic T cells were
plated (5 3 10
5 mL) with irradiated syngeneic spleen cells in the upper chamber of a semipermeable transwell, whereas spleen cells from naïve
6- to 8-week-old NOD mice were plated (1 3 107/mL) in the lower chamber. PBS, rat IgG (10 mg/mL), monoclonal antibody (10 mg/mL) to IL-5,
IL-13, or IFN-g was added to the upper wells. GAD65 peptide 524-543 (diagonal striped bar) or Concanavalin A (ConA) (black) was then added to
all upper chambers at a ﬁnal concentration of 10 mg/mL or 2.5 mg/mL, respectively. The control well contained the NOD spleen cells plus peptide
antigen in the lower chamber, but no GAD35Za cells in the upper chamber. Three days later, spleen cells in the lower chamber were recovered and
analyzed for IFN-g spot-forming cells (as in Fig. 1). The p524-543–speciﬁc results represent the mean and SD of triplicate wells and are repre-
sentative of three experiments.
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(Fig. 5B). These ﬁndings support the contention that IL-13
can deliver inﬂuential signals directly to effector T cells.
IL-13Ra2, a decoy receptor that negatively regulates IL-13
signaling (19), was not detected in any of the samples
above (data not shown).
In human cells, ligation of IL-13 to the high afﬁnity
IL-13Ra1/IL-4Ra heterodimer activates janus kinase 2 tyro-
sine kinase and subsequently the phosphorylation of STAT6
(20). Here, we show that TCR
+ T cells recovered from the
PLNs of young NOD mice respond to IL-13 by increasing the
phosphorylation of STAT6 (Figs. 6A and B), demonstrating
that the IL-13Ra1 expressed on the T cells was functional
and capable of transmitting intracellular signals following
ligand binding.
T-cell–speciﬁc IL-13Ra1 expression is prevalent in
the PLNs of young NOD mice. Islet inﬂammation in
NOD mice is characterized by distinct temporal and phe-
notypic stages. The early stage of insulitis, at 4–5 weeks of
age, is characterized by peri-insulitis with very limited
b-cell destruction. This benign period is followed by stages
of progressively enhanced islet destruction and inﬁltration
at 9–12 weeks of age, and sets the stage for the extensive
b-cell destruction that gives rise to hyperglycemia. To
explore the possibility of IL-13–mediated T-cell regulation
in the context of natural type 1 diabetes, we compared
patterns of IL-13Ra1
+ expression on T cells in 4-week-old
mice and 9- to 11-week-old mice. We found that the fre-
quency of IL-13Ra1
+ T cells was enhanced in the PLNs
of the young mice, compared with their ILNs or spleens
(Fig. 7I). Strikingly, there were signiﬁcantly more IL-13Ra1–
expressing T cells in the PLNs of young mice compared
with the older animals (Fig. 7B). On the other hand, there
was no signiﬁcant difference between 4- and 9-week-old
mice in the frequency of IL-13Ra1
+ T cells in the ILNs or
splenic populations (Fig. 7B). Although the actual per-
centages of IL-13Ra1
+ T cells varied, in individual experi-
ments (containing equal numbers of young and older mice)
the percentage of receptor positive cells was always sig-
niﬁcantly higher in the younger mice (Fig. 7B).
The ﬁndings above offer the possibility that the loss of
IL-13Ra1
+ T cells in the PLNs of NOD mice could correlate
with the increased severity of insulitis. Female NOD mice
bred and housed in our facility have a diabetes incidence
rate of greater than 80%, whereas less than 20% of the male
counterparts progress to hyperglycemia. When we evalu-
ated 4- and 9-week old male NOD mice (littermates of the
females) we found that both young and adult males dis-
played a pattern similar to that of 4-week-old females—
signiﬁcantly more IL-13Ra1
+ T cells in the PLNs than in the
corresponding inguinal or splenic lymphoid compartments
(Fig. 7B). Conversely, the frequency of IL-13Ra1
+ Tc e l l s
in ILNs and spleens from the older male mice was not
different from that of older female NOD mice or C57BL/6
control mice (Fig. 7B). An analysis of the pancreatic tissue
FIG. 4. Recombinant IL-13 directly antagonizes T-cell activities. A:
Pooled spleen cells (8 3 10
6/mL) from three 6-week-old female NOD
mice were stimulated in vitro with 10 mg/mL of p524-543 in the presence
or absence of recombinant cytokine (10 mg/mL) (IFN-g, IL-4, IL-5, or
IL-13). Three days later, the cells were resuspended and challenged
with p530-543–pulsed irradiated spleen cells. Forty-eight hours later,
the supernatants were tested by ELISA for the presence of IFN-g. The
results are representative of ﬁve experiments. B and C: Clonotypic
spleen T cells from NOD.BDC2.5.TCR.Tg mice (B) or CD4
+ T cells
puriﬁed from NOD mice (C) were stimulated in triplicate on anti-
CD3«–coated plates (1.0 mg/mL, black bar) in the presence or absence
of murine rIL-13 (0.2 or 1.0 ng/mL). Control wells were coated with PBS
(diagonal stripes). Two days later, the wells were pulsed with
3H-thymidine, then harvested and counted after an additional 18 h of
culture. The results are representative of two experiments. The per-
centages in the chart indicate the reduction in proliferation (counts per
minute [cpm]) compared with cells stimulated in the absence of rIL-13.
The P values were calculated using Student t test (*P = 0.05; **P <
0.005; ***P < 0.0005).
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1720 DIABETES, VOL. 60, JUNE 2011 diabetes.diabetesjournals.orgharvested from the same groups of animals revealed that
the level of invasive insulitis was highest among the older
female mice, whereas tissues from the older male mice
contained more normal islets and far fewer islets with the
invasive form of inﬂammation (Fig. 7C).
Because treatment with p524-538 ameliorates insulitis
and type 1 diabetes in young NOD mice, we wanted to
discover whether immunization with p524-538 could also
alter the expression of IL-13Ra1 on T cells in the PLNs of
postinsulitis female NOD mice. We found that number of
IL-13Ra1
+ T cells in the PLNs of 9-week-old female mice
treated with control peptide was signiﬁcantly lower than
that expressed on similar cells in young mice (Fig. 7D) and
comparable to untreated 9-week-old mice (Fig. 7D). On the
other hand, at 9 weeks of age mice treated with the GAD65
peptide retained a frequency of IL-13Ra1
+ T cells in PLNs
similar to that of 4-week-old mice (Fig. 7D).
DISCUSSION
Ongoing clinical trials have provided encouraging data
suggesting that treatment with the GAD65 protein will be
beneﬁcial in prolonging b-cell function in recent-onset hu-
man diabetes (21,22). Nevertheless, the molecular mecha-
nisms that govern GAD65-induced regulation of insulitis and
b-cell destruction remain unclear. Initially, immune de-
viation via the enhancement of IL-4–driven Th2 response
seemed a likely explanation for the improved outcome ob-
served in neonatal NOD mice successfully treated with
GAD65 protein or peptides (10,23,24). This contention was
strengthened by data indicating that NOD mice had de-
ﬁcient IL-4 responses, possibly as the result of reduced
numbers of IL-4–producing natural killer T cells (25–27)
and/or inadequate TCR signaling cascades (28). However,
the signiﬁcance of IL-4 in modulating islet autoimmunity
has been challenged in subsequent studies using IL-4–
deﬁcient NOD mice (29) or examining the role of natural
killer T cells in autoimmunity (30). Although neutralizing
antibodies provide strong evidence for IL-10 as an in-
ﬂuential cytokine, in many cases the correlation between
reduced islet pathology in NOD mice and the appearance
of regulatory cytokines such as IL-4 and IL-10 is indirect
and does not address the mechanism(s) by which the target
cells are engaged. Here, we show that an alternate Th2-like
cytokine, IL-13, is able to directly regulate GAD65-speciﬁc
Th1 cell–mediated autoimmunity. Importantly, IL-13Ra1e x -
pression on T cells may have an impact on the effector
functions of b-cell–speciﬁc T cells and islet injury during
t h ee a r l ys t a g eo ft y p e1d i a b e t e s ,ap e r i o dc h a r a c t e r i z e d
by benign insulitis (31). It is of particular interest that a dis-
tinct epitope on GAD65 is able to incite IL-13–producing
cells, either as p524-538 or as a determinant processed
from p524-543.
Prolonged administration of rIL-13 prevents or delays
the onset of insulitis and diabetes in young NOD mice, and
reduces the incidence in those with preexisting insulitis
(32). This Th2 cytokine has also been shown to have
protective effects in other models of inﬂammatory auto-
immune disease (33,34). However, until recently (35–37),
T cells were thought to be devoid of IL-13Ra1 expression
FIG. 5. NOD and BDC2.5.TCR.Tg T cells express IL-13Ra1. A: cDNA produced from puriﬁed NOD or BDC2.5.TCR.Tg CD4
+ cells, before or after
culture on anti-CD3–coated plates (72 h) was evaluated by real-time PCR to detect expression of IL-4R mRNA (upper panel) or IL-13Ra1 mRNA
(lower panel), relative to GAPDH. The CD4
+ EL4 thymoma line served as a negative control – transcripts for GAPDH were detected, whereas
mRNA for IL-13Ra1 or IL-4Ra was not detected (N.D.). B: NOD splenocytes were stained with antibodies to TCRab, CD4, and IL-13Ra1( upper
plot) or isotype control (lower plot). The plots are gated on TCR
+ populations. The numbers in the upper right quadrant indicate percentages of
TCR
+ cells that are also positive for the designated parameters. The plots shown are a representative experiments performed six times with similar
results.
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inﬂuence of the cytokine on inﬂammatory autoimmune
disease has largely been attributed to its effect on IL-13Ra1
+
monocytes and their potential to prevent the expansion of
autoreactive T cells (34). Our data, and that of others
(36,37), support a role for IL-13–induced signal transduction
in Th cells that produces altered gene expression and ef-
fector functions. IL-13 can speciﬁcally induce phosphory-
lation of the transcription factor STAT6 in T cells, as well as
increase the expression of GATA-3 (37). Our inhibition
experiments with the p524-speciﬁc T-cell clone GAD35Za
clearly showed that IL-13 suppressed native Th1 responses
that we observed in NOD mice. The regional enhancement
of IL-13Ra1 expression on T cells in the draining nodes of
the pancreas was speciﬁc to 4-week-old female NOD mice
and our 9-week-old male NOD that show resistance to
invasive insulitis and diabetes. This age-related loss of
IL-13Ra1 receptor expression may contribute to the col-
lapse of islet-speciﬁc tolerance, which has been reported
to instigate and perpetuate diabetes in the NOD mice (5).
Although our report focuses on CD4
+ T cells, we also
detected IL-13Ra1 expression on CD4-TCR
+ cells. It remains
to be determined whether treatment with p524 or rIL-13
is able to modulate the activities of islet-speciﬁcC D 8
+
T cells.
Lee et al. (35) show that IL-4 signaling through the
IL-4Ra/IL-13Ra1 heterodimer induces apoptosis in neonatal
IL-13Ra1–expressing Th1 cells upon antigenic challenge.
We found that exposure to IL-13 does not directly reduce
the number of autoreactive T cells in vitro, and systemic
delivery of the cytokine over several weeks was well tol-
erated in NOD mice (32), collectively suggesting the in-
duction of anergy or a functional shift in the inﬂammatory
milieu, rather than cell death, as the basis for our ﬁndings.
Th1-associated IFN-g and Th17-associated IL-17 can con-
tribute to inﬂammation, and the lack of either cytokine has
been shown to reduce or ameliorate inﬂammatory auto-
immune responses in several murine models of disease
(38–40). Upon exposure to either p524-538–speciﬁc T cells
or rIL-13, we detect a reduction in IFN-g production by
autoreactive p530-543–speciﬁc Th1 cells. We found that
the T-cell clone GAD35Za was able to inhibit the sponta-
neous Th1 responses to a dominant GAD65 epitope that
has been associated with progression of autoimmune
diabetes in wild-type NOD mice (10,41,42). Interestingly,
IL-13–deﬁcient mice exhibit increased proliferation of
antigen speciﬁcC D 4
+ and CD8
+ effector T cells (34), and
prophylactic treatment with IL-13 reduces the ability of
splenic cells to produce IFN-g in response to Concanavalin A
or anti-CD3. Because IFN-g is reported to antagonize the
generation of IL-17–producing Th17 cells (43), it was possi-
ble that suppression of IFN-g could promote a shift toward
a Th17-dominated response. However, we did not ﬁnd
that the IL-13–mediated reduction of IFN-g resulted in
production of IL-17 (data not shown). Furthermore, our
previous data show that p524-538 immunization blocks
the progression to diabetes in NOD mice, which is not
supportive of the conclusion that the treatment skews the
milieu toward a Th17 phenotype. Collectively, our data
conﬁrm the reports that T cells are able to express IL-13Ra1
FIG. 6. IL-13 stimulates the phosphorylation of STAT6 in T cells from the PLN. A: Serum-starved cells collected from the PLNs of three 4-week-old
NOD mice were cultured in the absence (middle plot) or presence of rIL-13 (1 ng/ml, left and right plots) for 30 min, and then stained with
antibodies to TCRab and the phosphorylated form of STAT6 (pSTAT6) (right plot) or isotype control (left plot). B: The mean number of TCR
+/
pSTAT6
+ cells was calculated from three independent experiments. P values were calculated using Student t test (*P < 0.05).
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1722 DIABETES, VOL. 60, JUNE 2011 diabetes.diabetesjournals.orgFIG. 7. IL-13Ra1 expression on T cells in the PLNs is enhanced in young prediabetic NOD mice. ILNs, PLNs, and spleens from 4- or 9-week-old NOD
mice were analyzed by ﬂuorescence-activated cell sorter for TCRab and IL-13Ra1 expression. A: Representative density plots from 4-week-old
(top plots) and 9-week-old (bottom plots) female NOD tissues. The plots shown are ungated populations, with the numbers indicating the per-
centages of cells in each quadrant. B: Quantitative analysis of IL-13Ra1
+ T cells in individual 4-week-old or 9–11-week-old NOD mice, female (F)
and male (M), or female C57BL/6 controls—each marker indicates an individual mouse. The means were calculated from seven experiments
performed under identical conditions; statistical analysis was performed using Student t test (**P < 0.005). C: The pancreas was collected from
three NOD mice, individuals in (B), ﬁxed, processed, and stained as described in the RESEARCH DESIGN AND METHODS. At least 50 islets were evaluated
for the severity of leukocyte inﬁltration: normal (ﬁlled bar), peri-insulitis (horizontal stripes), and invasive (diagonal stripes). D: PLNs from
female NOD mice immunized at 3 weeks of age with p524-538/IFA or HEL 11–25/IFA, were collected at 9 weeks of age and analyzed by ﬂow
cytometry. Untreated 4- and 9-week-old mice were used as controls. The data represents two experiments, with three mice per group. Statistical
analysis was performed using Student t test (*P < 0.05, **P < 0.005). N.S., not signiﬁcant.
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polarized CD4
+ T cells in NOD mice.
Although clone GAD35Za ameliorated diabetes when
transferred to young NOD mice (9), disease protection was
not elicited upon clone transfer to older NOD with pro-
nounced insulitis, or when cotransferred with diabeto-
genic splenocytes (data not shown), suggesting that
p524-538–speciﬁc regulation of autoreactive T cells is most
effective in the early stages of pancreatic autoimmunity.
This loss of regulatory activity could be related to the
temporal loss of IL-13Ra1 expression we observed in the
PLNs. Although the antigenic speciﬁcity of the IL-13Ra1
+ T
cells is unknown, our data show that the IL-13–producing
T cells (p524-538) and IL-13–responding T cells (b-cell
speciﬁc) are distinct. Therefore, since b-cell–speciﬁcT
cells are present in the peripheral blood of patients with
type 1 diabetes (44) and of at-risk individuals long before
the onset of hyperglycemia (45), as well as being detected
in the periphery of diabetes-free ﬁrst-degree relatives (46),
it would be of interest to discover whether differential
expression of the IL-13Ra1 on such T cells could serve as
a biomarker (47) for progressive b-cell destruction and
signal the onset of hyperglycemia. This could be accom-
plished most efﬁciently if staining for the receptor is com-
bined with the soluble major histocompatibility complex:
peptide technology that helped foster the identiﬁcation,
enumeration, and isolation of b-cell–speciﬁcTc e l l si n
humans (45,48). A biomarker for progressive immune
dysregulation could provide the underpinnings for earlier
introduction of GAD65 immunotherapy and the obvious
implications for improved beneﬁts.
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